The pediatric and neonatal testing kit market has seen considerable growth due to a variety of factors.
•There has been consistent growth in the market for pediatric and neonatal testing kits in the past years. The market value is projected to increase from $3.91 billion in 2024 to $4.21 billion in 2025, yielding a compound annual growth rate (CAGR) of 7.6%.
This considerable growth during the historic period can be associated with progress in pediatric and neonatal care, a heightened emphasis on child health, the development of healthcare infrastructure, amplified awareness about prenatal testing, and the changing regulatory environment.
The pediatric and neonatal testing kit market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of pediatric and neonatal testing kits is predicted to witness significant growth in the coming years, reaching $6.04 billion by 2029 with a compound annual growth rate (CAGR) of 9.4%.
This anticipated growth during the forecast span can be linked to the growing need for non-invasive testing methods, advancements in point-of-care pediatric testing, expanding investments in research on neonatal and pediatric care, and the acceptance of digital healthcare solutions. Key trends for the forecast duration comprise the evolution of quick and precise testing kits, the application of next-generation sequencing in pediatric diagnostics, the proliferation of newborn screening initiatives, amplified emphasis on metabolic testing in neonates, and the incorporation of artificial intelligence in diagnostic instruments.
The surge in cases of congenital disorders in infants is propelling the momentum of the pediatric and neonatal testing kit market. These disorders are present in infants at birth or occur during fetal growth. Screening of pediatric and neonatal diseases is crucial to identify any congenital defects, thereby allowing health professionals to address these issues early. For example, in February 2023, the World Health Organization (WHO), a specialized health agency of the United Nations based in Switzerland, reported that around 240,000 newborns globally succumb to congenital disorders within their first 28 days of life each year. Additionally, congenital conditions claim the lives of approximately 170,000 children between the ages of 1 month to 5 years. As such, the accelerating rate of congenital disorders fuels the growth of the pediatric and neonatal testing kits market.
The pediatric and neonatal testing kit market covered in this report is segmented –
1) By Test Type: Dried Blood Spot, Hearing Screening, Critical Congenital Heart Defect (CCHD), Other Test Types
2) By Product: Assay Kits And Reagents, Instruments
3) By Technology: Tandem Mass Spectrometry, Pulse Oximetry, Enzyme-Based Assays, DNA Based Assays, Electrophoresis, Others Technologies
4) By End User: Hospitals, Diagnostic Centers, Maternity And Specialty Clinics, Other End Users
Subsegments:
1) By Dried Blood Spot: Newborn Screening Panels, Genetic Testing, Infectious Disease Screening
2) By Hearing Screening: Automated Auditory Brainstem Response (ABR) Tests, Otoacoustic Emissions (OAE) Tests, Portable Hearing Screening Devices
3) By Critical Congenital Heart Defect (CCHD): Pulse Oximetry Screening Kits, Echocardiography Screening Tools, Clinical Assessment Protocols
4) By Other Test Types: Blood Gas Analysis Kits, Urine Testing Kits, Infectious Disease Testing, Point-of-Care Testing Devices
The pediatric and neonatal testing kits market is seeing a significant trend towards the creation of unique screening tests. Major players in the market are concentrating their efforts on the development of innovative screening kits, such as mass screening tests, in order to maintain their market position. In May 2024, for example, Shimadzu Techno-Research, Inc., a contract analysis company based in Japan, launched a new contract service to perform PCR testing to enhance newborn mass screening. This service tests for severe rare diseases such as Severe Combined Immunodeficiency (SCID), B-cell Deficiency (BCD), and Spinal Muscular Atrophy (SMA), with the aim of quickly identifying these conditions after birth to allow for immediate intervention and treatment, thereby improving the health of newborns. Currently, this service is available in 40 of Japan's 47 prefectures, but there are plans in place to expand testing to all newborns through public funding. By collaborating with hospitals and birthing facilities, STR aims to enhance the health and well-being of newborns across Japan.
Major companies operating in the pediatric and neonatal testing kit market include:
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Medtronic Plc
• Siemens Healthineers
• GE Healthcare GmbH
• Eurofins Scientific SE
• Trivitron Healthcare Pvt Ltd.
• Hologic Inc.
• PerkinElmer Inc.
• Quidel Corporation
• Bio-Rad Laboratories Inc.
• QIAGEN NV
• Natus Medical Incorporated
• BioFire Diagnostics LLC
• Luminex Corporation
• Meridian Bioscience Inc.
• MP Biomedicals LLC
• ELITech Group SAS
• Baebies Inc.
• Labsystems Diagnostics Oy
• Advacare Pharma LLP
• Beckman Coulter Inc.
• JETA Molecular BV
• EpigenTek Group Inc.
• ZenTech SA
• Hangzhou Testsea Biotechnology Co. Ltd.
North America was the largest region in the pediatric and neonatal testing kit market in 2024. The regions covered in the pediatric and neonatal testing kit market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.